Continuation of Research and Development Activities
First written in FY2021-Q3. 7 of 12 entries say "Restated". Latest entry: FY2024-Q3.
99 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥20.284 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The disclosure continues to state that there were no material changes in research and development activities and reports research and development expenses for the cumulative third quarter. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥16.049 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」
The disclosure continues to state that there were no material changes in research and development activities and reports research and development expenses for the cumulative second quarter. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥6.801 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The disclosure continues to state that there were no material changes in research and development activities and reports research and development expenses for the quarter. - FY2023AdvancedAnnual report
「Total research and development expenses for the fiscal year amounted to ¥33.070 million.」
Research and development expenses increased from ¥29.027 million in the previous fiscal year to ¥33.070 million. The company continued process development and contract projects in pharmaceuticals, formulation development and prototyping in health foods, and application development, water treatment equipment design, and joint development with overseas manufacturers in chemicals. - FY2023-Q3Increase in development expenses in the chemicals businessAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥20.915 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
While stating that there were no material changes in research and development activities, the disclosure explains that development expenses in the chemicals business increased due to more testing associated with development and additional personnel. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥12.726 million. There were no material changes in the status of the company's research and development activities during the cumulative second quarter.」
The disclosure continues to state that there were no material changes in research and development activities and reports research and development expenses for the cumulative second quarter. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥6.268 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The disclosure continues to state that there were no material changes in research and development activities and reports research and development expenses for the first quarter. - FY2022AdvancedAnnual report
「By meeting customer requests and other measures, the company generated new sales from 38 products during the fiscal year, and research and development expenses in the health foods business amounted to ¥1.052 million.」
Research and development expenses amounted to ¥29.027 million. In the health foods business, 38 products generated new sales, while the chemicals business made progress in joint development and field testing of a biodiesel refining unit. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥15.110 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The disclosure reiterates that there were no material changes in research and development activities and reports research and development expenses for the cumulative third quarter. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥5.716 million. There were no material changes in the status of the company's research and development activities during the cumulative first quarter.」
The disclosure reiterates that there were no material changes in research and development activities and reports research and development expenses for the first quarter. - FY2021AdvancedAnnual report
「By meeting customer requests and proposing formulations capable of extending shelf life, the company generated new sales from 21 products during the fiscal year, and research and development expenses in the health foods business amounted to ¥1.622 million.」
Research and development expenses increased from ¥18.071 million to ¥32.020 million. In the health foods business, 21 products generated new sales, while in the chemicals business, a highly crosslinked ion-exchange resin was commercialized. - FY2021-Q3First statedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥18.071 million. There were no material changes in the status of the company's research and development activities during the cumulative third quarter.」
The disclosure reports research and development expenses of ¥18.071 million and states that there were no material changes in the status of research and development activities.